Image via Simply Wall St
nCino: Product Launch
nCino reported strong Q1 2027 results including revenue and subscription growth, shift to GAAP operating profit, and fresh customer wins, despite broader stock price weakness.
Source: Simply Wall St
The leadership read
Product momentum tends to widen the sector product and commercial leadership bench strength.
Market context: MitchelLake's Talent Market Index sits at 113.7 (Hot), up 13.7 on the prior month; Americas hiring signal is running easing (-3pts).
nCino: 2 signals in the last 90 days; 0.1% of MitchelLake's EMEA signal flow; 2 tracked across 54 days.
Also at nCino →
More signals across Americas
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Predactiv →Predactiv launched a Model Context Protocol (MCP) Server and Platform API to integrate audience intelligence capabilities into generative AI tools and workflows
Product Launch · Americas
NewsGuard →NewsGuard launched NewsGuard AI, a news-focused chatbot built exclusively on vetted sources from a database of ~12,000 publishers evaluated for reliability. Platform generates revenue for cited publishers and incorporates debunking safeguards.
Product Launch · Americas
Descartes Systems Group →Descartes Systems Group launched AuditLog, a new review management and audit logging capability within Descartes MyCarrierPortal to help freight brokers, 3PLs, and shippers create auditable, transparent carrier selection processes with standardized workflows and management oversight.
Product Launch · Americas
Carnival Cruise Line →Carnival Cruise Line launches 'Frightfully Fun' Halloween-themed cruise series scheduled for September-October 2026 across its fleet
Product Launch · Americas
SandboxAQ →SandboxAQ announced a new virtual screening solution for GPCR drug discovery, accelerated by NVIDIA BioNeMo, designed to help drug developers identify promising candidates faster and at lower cost.
Intelligence powered by Autonodal ↗